It is estimated that around 50% of human cancers have a mutated form of p53 and over 17% have amplifications of the MDM2 gene; each of these alterations, separately or together, contributes to poor prognosis and treatment failure [10,12,31]. This evidence concerns the gene TP53 and cancer.